ABBOTT LABORATORIES — Director's Dealing 2019

Feb 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-02-22

Reporting Person: Contreras Jaime (Senior Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-22	Common shares without par value	A	14698	—	Acquired	125999	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-22	Option (right to buy)	$75.90	A	77045	Acquired	2029-02-21	Common shares (77045)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	22	Indirect
Common shares without par value	84579	Indirect
Common shares without par value	2595	Indirect
Common shares without par value	12081	Indirect

Footnotes

F1: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of February 22, 2019.

F3: Held in the Jaime Contreras Marvan 2006 Living Trust. The reporting person is sole trustee of the trust. The trust is revocable.

F4: The reporting person disclaims beneficial ownership of all securities held by his spouse.

F5: Held in spouse's living trust. The reporting person's spouse is sole trustee of the trust. The trust is revocable. The reporting person disclaims beneficial ownership of these securities.

F6: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,681 on February 22, 2020, 25,682 on February 22, 2021, and 25,682 on February 22, 2022.